Alimera Sciences (ALIM) Receiving Somewhat Positive Media Coverage, Study Finds
Media coverage about Alimera Sciences (NASDAQ:ALIM) has been trending somewhat positive on Tuesday, Accern Sentiment reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alimera Sciences earned a news impact score of 0.18 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.3085525942582 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have effected Accern’s rankings:
- ETFs with exposure to Alimera Sciences, Inc. : November 9, 2017 (finance.yahoo.com)
- Alimera Sciences Announces Nine iluvien® data sets to be Presented at 2017 american academy of ophthalmology – GlobeNewswire (press release) (globenewswire.com)
- Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017 (finance.yahoo.com)
- Alimera Sciences’ CEO Dan Myers to Present During Ophthalmology Innovation Summit at American Academy of … – GlobeNewswire (press release) (globenewswire.com)
Shares of Alimera Sciences (ALIM) opened at $1.25 on Tuesday. Alimera Sciences has a 52 week low of $1.04 and a 52 week high of $1.72. The company has a current ratio of 4.84, a quick ratio of 4.65 and a debt-to-equity ratio of -0.71.
A number of brokerages have weighed in on ALIM. HC Wainwright set a $5.00 target price on Alimera Sciences and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Zacks Investment Research lowered Alimera Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Cowen and Company set a $3.00 target price on Alimera Sciences and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, ValuEngine raised Alimera Sciences from a “strong sell” rating to a “sell” rating in a research report on Friday, October 20th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Alimera Sciences has a consensus rating of “Hold” and a consensus price target of $3.38.
ILLEGAL ACTIVITY NOTICE: “Alimera Sciences (ALIM) Receiving Somewhat Positive Media Coverage, Study Finds” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://theolympiareport.com/2017/11/14/alimera-sciences-alim-receiving-somewhat-positive-media-coverage-study-finds.html.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.